News

Europe’s firms ramp up R&D
Enlarge image

BusinessEU

Europe’s firms ramp up R&D

07.12.2012 - According to the 2011 EU Industrial R&D Investment Scoreboard, the 400 leading European companies invested about €132bn, a plus of 6.1% over 2009.

R&D investment by top EU companies recovered strongly in 2010. The annually published Scoreboard collects information on the top 1000 EU companies and 1000 non-EU companies investing the largest sums in research and development. What seems to be a positive trend as a first glance, shows some worrying trends at closer inspection. The study, which was commissioned by the European Commission, has shown that EU companies as a whole are lagging behind major competitors from the US and some Asian economies on R&D growth. While EU-based companies increased R&D expenditures by 6.1%, US-companies have spent 10% more. The increase was even larger in Taiwan (17.8%), South Korea (20.5%) and China(29.5%).

The global top 50, in terms of total R&D investment, includes 15 EU companies, 18 US firms and 13 from Japan. Two pharmaceutical companies occupied the top spots: Roche from Switzerland (€7.2bn) followed by Pfizer from the US (€7bn). A ray of light: A poll with some 190 mainly larger EU-companies surveyed in the Scoreboard revealed that they expect to maintain robust R&D investment increases (average 4% p.a.) over the next three years. This could be seen as a positive and stable trend for R&D investment growth, as observed before the 2008 economic and financial crises.

The Pharmaceuticals & Biotechnology sector has strengthened its position as the largest sector for R&D, its expenditures grew by 6.2% in 2010, slightly more than in 2009. The other two top sectors, Technology Hardware & Equipment and Automobiles & Parts are recovering from the significant reductions observed in the past Scoreboard (from -6.4% to 3.5% and from -11.6% to 0% respectively). Interestingly, all three sectors increased net sales more than they increased R&D investments.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science sees room for further improvement. „We need quick adoption and implementation of recent and up-coming European Commission proposals on the unitary patent, on standards, public procurement and risk capital“, she said. 

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/europes-firms-ramp-up-rd.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR27.2%
  • MOLOGEN7.65 EUR3.4%
  • HBM85.50 CHF3.1%

FLOP

  • PAION2.20 EUR-32.3%
  • 4SC0.80 EUR-29.8%
  • CYTOS0.16 CHF-23.8%

TOP

  • SANTHERA81.90 CHF2267.1%
  • CO.DON2.69 EUR195.6%
  • PAION2.20 EUR155.8%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014